Domo, Inc.
NASDAQ:DOMOSoftware - Application
+$0.43 today
- Market cap
- $155.39M
- Beta
- 1.77
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.28
Volume 3.18M
Average 1.39M
DOMO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Domo, Inc.NASDAQ: DOMO
Research & Development · Q1 FY2027 · quarter ended Apr 2026
Research & development declines year over year
Q1 FY2027 research & development of $18.65M fell 6.6% year over year, ahead of the -10.9% change in trailing-twelve-month research & development. Sequentially, it fell 3.0% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Research & development amounted to 24.2% of revenue in FY2026, down 3.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -6.6% holds above the trailing-twelve-month pace of -10.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 77.19M USD
- Year-over-year change
- -12.2%
- 4-year CAGR
- -1.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | 77.19M | -12.2% |
| FY2025 | 2025-01-31 | 87.9M | +3.4% |
| FY2024 | 2024-01-31 | 85.05M | -10.6% |
| FY2023 | 2023-01-31 | 95.09M | +17.4% |
| FY2022 | 2022-01-31 | 81.03M | — |
Research & Development vs competitors
How DOMO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.9% is the 8th highest of 9, against a peer median of +4.4%.
- Research & development amounts to 23.8% of revenue for DOMO, versus a peer median of 17.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $110.37M USD | +14.6% | +5.3% | 11.9% | |
| LTM Mar 2026 | $108.55M USD | +7.9% | -3.0% | 35.9% | |
| LTM Mar 2026 | $105M USD | +2.7% | +18.1% | 22.4% | |
| LTM Apr 2026 | $75.88M USD | -10.9% | -6.7% | 23.8% | |
| LTM Mar 2026 | $45.54M USD | +3.0% | +11.7% | 30.4% | |
| LTM Mar 2026 | $44.12M USD | +5.7% | +13.1% | 17.7% | |
| LTM Mar 2026 | $40.48M USD | +2.6% | -10.5% | 7.2% | |
| LTM Mar 2026 | $28.96M USD | +16.8% | — | 71.8% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.28M CNY | -94.8% | -61.3% | — |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| FY2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding DOMO) | — | +4.4% | +5.3% | 17.7% | |
Competitors are the stored peer set for DOMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 257.96M | 308.65M | 318.99M | 317.04M | 318.86M |
| Cost of Revenue | 67.15M | 73.08M | 75.47M | 80.99M | 79.74M |
| Gross Profit | 190.82M | 235.57M | 243.52M | 236.05M | 239.12M |
| Gross Margin | 74.0% | 76.3% | 76.3% | 74.5% | 75.0% |
| Research & Development | 81.03M | 95.09M | 85.05M | 87.9M | 77.19M |
| Selling, General & Admin | 198.26M | 229.35M | 213.35M | 206.83M | 201.03M |
| Operating Expenses | 279.29M | 324.44M | 298.4M | 295.33M | 278.22M |
| Depreciation & Amortization | 5.36M | 5.29M | 6.62M | 9.24M | 28.75M |
| EBITDA | (83.11M) | (82.96M) | (47.51M) | (51.69M) | (28.84M) |
| EBITDA Margin | -32.2% | -26.9% | -14.9% | -16.3% | -9.0% |
| Operating Income | (88.47M) | (88.87M) | (54.88M) | (59.28M) | (39.1M) |
| Operating Margin | -34.3% | -28.8% | -17.2% | -18.7% | -12.3% |
| Interest Income | 13.4M | 15.5M | 0 | 0 | 0 |
| Interest Expense | 14.1M | 15.5M | 0 | 19.8M | 0 |
| Other Income / Expenses | (14.1M) | (15.5M) | (19.43M) | (21.44M) | (18.49M) |
| Income Before Tax | (102.57M) | (104.37M) | (74.31M) | (80.73M) | (57.58M) |
| Pre-Tax Margin | -39.8% | -33.8% | -23.3% | -25.5% | -18.1% |
| Income Tax Expense | (461K) | 1.18M | 1.26M | 1.21M | 1.76M |
| Net Income | (102.11M) | (105.55M) | (75.57M) | (81.94M) | (59.34M) |
| Net Margin | -39.6% | -34.2% | -23.7% | -25.8% | -18.6% |
| EPS (Basic) | (3.19) | (3.10) | (2.10) | (2.13) | (1.45) |
| EPS (Diluted) | (3.19) | (3.10) | (2.10) | (2.13) | (1.45) |
| Weighted Avg Shares | 32.02M | 34.09M | 36.05M | 38.5M | 40.98M |
| Weighted Avg Shares (Diluted) | 32.02M | 34.09M | 36.05M | 38.5M | 40.98M |
Domo, Inc.
NASDAQ:DOMO
Intrinsic Alpha fair value
Locked
Current Price
$3.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.